Canal-U

Mon compte

Résultats de recherche

Nombre de programmes trouvés : 183
Label UNT Conférences

le (13m24s)

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Target populations: How do we risk-stratify? Are additional biomarkers helpful?

Title : Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Target populations: How do we risk-stratify? Are additional biomarkers helpful?Speaker: Wolfgang KOENIG, Ulm, GERDiscussant: Adrian HERNANDEZ, Durham, USAAbstract : LDL cholesterol (LDL-C) is causally involved in the atherosclerotic process and presents the major lipid variable for risk assessment, and statin therapy is guided by different levels of target LDL-C according to the absolute risk of the patient. Statins have revolutionized the treatment of hypercholesterolemia in patients without but also with manifest atherosclerosis and numerous trials since 4S have consistently documented a decrease in cardiovascular risk associated with decreases in LDL-C. Thus, ...
Voir la vidéo
Label UNT Conférences

le (46m31s)

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Save life and save cost with ivabradine.

Title : Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Save life and save cost with ivabradine.Speaker: Martin COWIE, London, GBRAbstract :  Clinical evidence suggests that an elevated resting heart rate is a risk factor for mortality and morbidity in heart failure (HF) patients. SHIfT examined the effect of adding ivabradine, a heart rate lowering therapy, to optimised standard therapy in HF patients with a heart rate ?70bpm, in sinus rhythm and with left ventricular systolic dysfunction.1 Ivabradine plus standard therapy significantly reduced the risk of a primary composite event (CV death and hospitalisation for worsening HF) versus standard therapy (hazard ...
Voir la vidéo
Label UNT Conférences

le (10m31s)

Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients

Title : Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patientsSpeakers: Chris MIX, Amgen, USA - David WHEELER, London, GBRDiscussant: Ziad MASSY, Boulogne-Billancourt, FRAAbstract : EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients.The extracellular calcium-sensing receptor (CaR) was first described in the parathyroid gland. Recent studies have shown that the CaR is also expressed in cardiomyocytes, peri-vascular nerves of the adventitia, vascular smooth muscle cells, and endothelial cells, but our understanding of its physiological functions in the cardiovascular system remains incomplete. A variety of studies point to a possible role of CaR activity modulation ...
Voir la vidéo
Label UNT Conférences

le (9m25s)

Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients (debates).

Title : Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients (debates).Speakers: Chris MIX, Amgen, USA - David WHEELER, London, GBRDiscussant: Ziad MASSY, Boulogne-Billancourt, FRA.Abstract : EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients (debates).L’auteur n’a pas transmis de conflit d’intérêt concernant les données diffusées dans cette vidéo ou publiées dans la référence citée.Conférence enregistrée : 9th Global Cardiovascular Clinical Trialists Forum • Paris 2012 Cardiovascular prevention in chronic kidney disease. New therapeutic options and future opportunities- Cardiovascular events are 10 to 20 fold higher in CKD patients. Heart failure is the main cardiovascular complication ...
Voir la vidéo
Label UNT Conférences

le (11m35s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Impact of major clinical trials on ESC Chronic Heart Failure 2012 guidelines. Game changer trials: EMPHASIS-HF, SHIFT, Devices…

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Impact of major clinical trials on ESC Chronic Heart Failure 2012 guidelines. Game changer trials: EMPHASIS-HF, SHIFT, Devices…Speaker: Faiez ZANNAD, Nancy, FRDiscussant: John CLELAND, Hull, GBRAbstract : Impact of major clinical trials on ESC Chronic Heart Failure 2012 guidelines. Game changer trials: EMPHASIS-HF, SHIFT, Devices…L’auteur n’a pas transmis de conflit d’intérêt concernant les données diffusées dans cette vidéo ou publiées dans la référence citée.9th Global Cardiovascular Clinical Trialists Forum • Paris 2012 Multidisciplinary expert workshop : achievements challenges and barriers to implantation of the ESC 2012 chronic heart failure guidelines.Chairpersons: Alain ...
Voir la vidéo
Label UNT Conférences

le (32m49s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Is it always safe to believe in class effect: Spironolactone vs. eplerenone differences and clinical relevance?

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Is it always safe to believe in class effect: Spironolactone vs. eplerenone differences and clinical relevance?Speaker: Bertram PITT, Ann Arbor, USAAbstract : Is it always safe to believe in class effect: Spironolactone vs. eplerenone differences and clinical relevance?L’auteur n’a pas transmis de conflit d’intérêt concernant les données diffusées dans cette vidéo ou publiées dans la référence citée.9th Global Cardiovascular Clinical Trialists Forum • Paris 2012 Multidisciplinary expert workshop : achievements challenges and barriers to implantation of the ESC 2012 chronic heart failure guidelines.Chairpersons: Alain COHEN-SOLAL, Paris, FRA - Adrian VOORS, Groningen, ...
Voir la vidéo
Label UNT Conférences

le (16m37s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic markers be studied?

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic markers be studied?Speaker: Jim JANUZZI, Boston, USADiscussant: James SNIDER, Critical Diagnostics, USAAbstract : How should Diagnostic and Prognostic Markers BeStudied? The measurement of biomarkers for diagnosis and prognosis in heart disease has changed the fundamental way that patients are evaluated, and has led to a literal explosion of studies exploring both novel applications of established biomarkers as well as the discovery of newer biological markers. With the rise in interest in novel biomarkers has come a clear heterogeneity in the approach with which these potentially important tests have ...
Voir la vidéo
Label UNT Conférences

le (7m59s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluating the merits of a novel marker

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluating the merits of a novel markerSpeaker: Stefan BLANKENBERG, Hamburg, GERDiscussant: Nancy GELLER, Bethesda, USAAbstract : Best statistical methods for evaluating the merits of a novel markerThe measurement of biomarkers for diagnosis and prognosis in heart disease has changed the fundamental way that patients are evaluated, and has led to a literal explosion of studies exploring both novel applications of established biomarkers as well as the discovery of newer biological markers. With the rise in interest in novel biomarkers has come a clear heterogeneity in the approach ...
Voir la vidéo
Label UNT Conférences

le (10m1s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : debate : Best statistical methods for evaluating the merits of a novel marker (debates).

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : debate : Best statistical methods for evaluating the merits of a novel marker (debates).Speaker: Stefan BLANKENBERG, Hamburg, GERDiscussant: Nancy GELLER, Bethesda, USAAbstract : debate : Best statistical methods for evaluating the merits of a novel marker (debates).The measurement of biomarkers for diagnosis and prognosis in heart disease has changed the fundamental way that patients are evaluated, and has led to a literal explosion of studies exploring both novel applications of established biomarkers as well as the discovery of newer biological markers. With the rise in interest in novel biomarkers has come ...
Voir la vidéo
Label UNT Conférences

le (17m30s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Biomarker guided-therapy: Are there other endpoints besides mortality that matter? Selecting the best outcome measures

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Biomarker guided-therapy: Are there other endpoints besides mortality that matter? Selecting the best outcome measuresSpeaker: Michael FELKER, Durham, USAAbstract : Biomarker guided-therapy: Are there other endpoints besides mortality that matter? Selecting the best outcome measuresThe measurement of biomarkers for diagnosis and prognosis in heart disease has changed the fundamental way that patients are evaluated, and has led to a literal explosion of studies exploring both novel applications of established biomarkers as well as the discovery of newer biological markers. With the rise in interest in novel biomarkers has come a clear ...
Voir la vidéo

 
FMSH
 
Facebook Twitter
Mon Compte